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accepted June 18,offee, after water, is the most widely consumed beverage in the United States, and is the principal source of
caffeine intake among adults. The biological effects of coffee may be substantial and are not limited to the actions
of caffeine. Coffee is a complex beverage containing hundreds of biologically active compounds, and the health
effects of chronic coffee intake are wide ranging. From a cardiovascular (CV) standpoint, coffee consumption may
reduce the risk of type 2 diabetes mellitus and hypertension, as well as other conditions associated with CV risk such
as obesity and depression; but it may adversely affect lipid proﬁles depending on how the beverage is prepared.
Regardless, a growing body of data suggests that habitual coffee consumption is neutral to beneﬁcial regarding the
risks of a variety of adverse CV outcomes including coronary heart disease, congestive heart failure, arrhythmias,
and stroke. Moreover, large epidemiological studies suggest that regular coffee drinkers have reduced risks of
mortality, both CV and all-cause. The potential beneﬁts also include protection against neurodegenerative diseases,
improved asthma control, and lower risk of select gastrointestinal diseases. A daily intake ofw2 to 3 cups of coffee
appears to be safe and is associated with neutral to beneﬁcial effects for most of the studied health outcomes.
However, most of the data on coffee’s health effects are based on observational data, with very few randomized,
controlled studies, and association does not prove causation. Additionally, the possible advantages of regular coffee
consumption have to be weighed against potential risks (which are mostly related to its high caffeine content)
including anxiety, insomnia, tremulousness, and palpitations, as well as bone loss and possibly increased risk of
fractures. (J Am Coll Cardiol 2013;62:1043–51) ª 2013 by the American College of Cardiology FoundationCoffee is second only to water as the most widely consumed
beverage in the United States. U.S. coffee consumption has
been increasing for the past 2 decades, and today about two
thirds of American adults drink coffee on a daily basis (1).
Each day Americans drink >400 million cups of coffee, and
the United States consumes more coffee than any other
nation (1). Even potentially small health beneﬁts or risks
associated with coffee intake may have important public
health implications given its widespread popularity. Many
misconceptions persist regarding the health-related effects of
coffee. The purpose of this article is to review existing data
regarding the effects of long-term coffee consumption, with
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2013.Biologically Active Constituents of Coffee
Coffee is a complex beverage containing >1,000 compounds.
Among the many with known biological activity are caffeine
(a potent stimulant and bronchodilator), diterpene alcohols
(which can increase serum cholesterol), and chlorogenic acid
(one of many types of antioxidant and anti-inﬂammatory
compounds found in coffee). Caffeine is by far the most
studied compound in coffee, and this agent largely accounts for
the inherently habit-forming nature of the beverage. Coffee
accounts for 71%of caffeine intake amongAmerican adults (soft
drinks are the primary source of caffeine for children and
adolescents) (2).The caffeine content of coffee is highly variable,
even when the coffee beverage is obtained from the same outlet
(3). A standard 8-oz cup of brewed coffee can contain anywhere
fromw95 to 200mgof caffeine.However, coffee is increasingly
served in containers that are considerably larger (e.g., 12 to
16 oz), typically delivering 180 to 300mg of caffeine per serving
(4). Brewed decaffeinated coffee still contains caffeine, albeit at
much lower doses that usually range from 5 to 15 mg per 8 oz.
Given the focus on caffeine for much of the research around
coffee, the terms caffeine and coffee are often conﬂated in both
Abbreviations
and Acronyms
AF = atrial ﬁbrillation
BP = blood pressure
CHD = coronary heart
disease
CHF = congestive heart
failure
CI = conﬁdence interval
CV = cardiovascular
HTN = hypertension
LDL = low-density lipoprotein
MI = myocardial infarction
RCT = randomized,
controlled trial
RR = relative risk
T2DM = type 2 diabetes
mellitus
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1044the biomedical literature and pub-
lic perception. However, the terms
are not synonymous, and the bio-
logical effects of coffee cannot be
reduced to the isolated effects of the
caffeine that it contains. Here we
discuss the evidence of coffee’s
effects on cardiometabolic risk
factors (i.e., hypertension [HTN],
insulin resistance, dyslipidemia),
CV disease (i.e., coronary heart di-
sease [CHD], congestive heart
failure [CHF], arrhythmias, and
stroke), and mortality (CV and all-
cause). We also discuss other po-
tential health beneﬁts and health
risks of coffee consumption, dis-
tinguishing between data speciﬁ-
cally on caffeine and data on coffee.Coffee and Blood Pressure
Hypertension is a strong independent risk factor for stroke
and CHD. Coffee consumption has been associated with
acute increases in blood pressure (BP) in caffeine-naive
people but exerts negligible effects on the long-term levels
of BP in habitual coffee drinkers (5). The acute effects of
coffee are transient, and, with regular intake, tolerance
develops to the hemodynamic and humoral effects of caf-
feine (6). A recent meta-analysis of 10 randomized, con-
trolled trials (RCTs) and 5 cohort studies assessed BP
and the incidence of HTN in coffee consumers. Nonsig-
niﬁcant mean changes in systolic BP of 0.55 mm Hg (95%
conﬁdence interval [CI]: 2.46 to 1.36) and diastolic
BP 0.45 mm Hg (95% CI: 1.52 to 0.61) were noted in
coffee drinkers compared with the control group. Evidence
analyzed from this large study showed no clinically impor-
tant effects of long-term coffee consumption on BP or risk
of HTN (7). Studies and reviews done previously have also
come to similar conclusions (8). The Nurses’ Health Study,
with 1.4 million person-years of follow-up, demonstrated
that daily intake of up to 6 cups of coffee was not associated
with an increased risk of HTN (9).
Caffeine is the major acute BP-increasing compound
found in coffee, but other compounds present in coffee may
counteract these acute pressor effects. A study of 15
volunteers, including 6 habitual and 9 nonhabitual coffee
drinkers, demonstrated that intravenous caffeine infusion
induced similar increases in muscle sympathetic activity and
BP in the 2 groups. In contrast, coffee drinking increased
BP in nonhabitual drinkers but not in the habitual coffee
drinkers, despite comparable increases of muscle sympa-
thetic activity and plasma caffeine levels in the 2 groups after
coffee ingestion. The authors concluded that caffeine is not
solely responsible for the CV effects associated with short-
and long-term coffee consumption (10).Coffee and Insulin Sensitivity
Antioxidants in coffee, such as chlorogenic acid, have been
recognized to improve glucose metabolism and insulin sensi-
tivity (11). A recently published randomized study found that
consumption of 5 cups of coffee per day increased adiponectin
levels and decreased insulin resistance (12). Caffeine acutely
activates 50-adenosine monophosphate–activated protein
kinase and insulin-independent glucose transport in skeletal
muscle (13). Studies in rat models conﬁrmed that it upregu-
lates insulin-like growth factor 1 signaling, which in turn
enhances insulin sensitivity as well as insulin secretion (14).
A systematic review of 9 cohort studies compared
minimal to low coffee consumption (<2 cups/day) with that
of heavy coffee consumption (6 cups/day) for the risk of
the development of type 2 diabetes mellitus (T2DM). These
researchers concluded that the risk of the development of
T2DM was lowest in subjects who drank >6 cups daily
(relative risk [RR]: 0.65; 95% CI: 0.54 to 0.78) and also was
signiﬁcantly reduced for subjects who consumed 4 to 6 cups
daily (RR: 0.72; 95% CI: 0.62 to 0.83) (Fig. 1) (15). A
prospective study of >88,000 women 26 to 46 years of age
established a linear relationship of coffee consumption with
the reduction in T2DM, whereby even small amounts of
coffee on a daily basis conferred beneﬁt (16). Associations
were similar for noncaffeinated and caffeinated coffee.Coffee and Serum Lipids
Coffee contains cholesterol-increasing compounds classiﬁed
as diterpenes, including cafestol and kahweol (17). Impor-
tantly, the concentration of these compounds depends on
how coffee is prepared. Boiled coffee has higher concen-
trations because diterpenes are extracted from the coffee
beans by prolonged contact with hot water. By comparison,
brewed/ﬁltered coffee, because of the much shorter contact
with hot water and retention of diterpenes by ﬁlter paper,
has a much lower concentration of cafestol and kahweol.
The effect of coffee on serum lipid levels was studied in
107 young adults with normal cholesterol levels followed for
12 weeks. Coffee was brewed by 2 common methods,
ﬁltering and boiling, and the participants were assigned to 1
of 3 groups: drinking 4 to 6 cups of boiled coffee per day, 4
to 6 cups of ﬁltered coffee per day, or no coffee, for a period
of 9 weeks. A signiﬁcant increase in total cholesterol and
a nonsigniﬁcant increase in low-density lipoprotein (LDL)
cholesterol were observed in participants consuming boiled
coffee. On the other hand, there was no signiﬁcant differ-
ence in the change in serum total or LDL cholesterol levels
between the ﬁltered-coffee group and the group who drank
no coffee (18). These results were replicated in a meta-
analysis of 14 RCTs in which the consumption of boiled
coffee dose-dependently increased serum total and LDL
cholesterol concentrations, whereas the consumption of
ﬁltered coffee resulted in very little change in serum
cholesterol (19). A large cohort of 132,000 men and women
Figure 1
The Relationship Between Coffee Consumption and Subsequent Type 2 Diabetes Mellitus in Different Categories of
Coffee Consumption
The center of each black square is placed at the summary point estimate; the area of the square is proportional to the population size; and each vertical line shows the 95%
conﬁdence interval about the summary estimate. Reprinted with permission from Husley et al. (15).
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Health Study without history of CV disease and cancer also
found no impact of ﬁltered coffee on total cholesterol, LDL
and high-density lipoprotein levels (20).
Conversely, tea, however, shares many of the health
effects of coffee and has a favorable effect on the lipid
proﬁles, especially the LDL/high-density lipoprotein ratio,
which is in contrast to the lipid effects of unﬁltered coffee
consumption (21).
Coffee and CHD
Decades-old studies suggested coffee consumption might
cause adverse CV effects including an increased risk of
myocardial infarction (MI) (22,23). However, unmeasured
confounding probably ﬂawed those early studies; in subse-
quent analyses when other important health-related variables
(such as smoking, alcohol use, saturated fat consumption,
physical activity, and body mass index) were adjusted for, the
risk of mortality, both all-cause and CV related, appeared to
be lower in regular coffee drinkers (Figs. 2A and 2B) (24,25).
Many epidemiological studies have evaluated the potential
effects of coffee on CHD, and these individual studies have
generally shown neutral effects. However, a meta-analysis of
21 independent prospective cohort studies from January
1966 to January 2008 suggested that moderate coffee
consumption may decrease the long-term risk of CHD (26).
In this study, 15,599 CHD cases developed in 407,806
participants. Compared with the light-to-absent coffee
consumption (<1 cup/day in the United States or 2 cups/
day in Europe), moderate coffee consumption (>1 or 2 cups
daily, respectively) was associated with signiﬁcantly lower
rates of CHD in the entire group of men and women with
an RR of 0.87 (p ¼ 0.001).
Several studies have suggested that it is safe for patients
with established CHD to continue their habitual coffee
consumption. An RCT involving 103 patients with acuteST-segment elevation MI evaluated the effect of acute
ingestion (immediate effects) of coffee on autonomic function
and CV health. Coffee ingestion was associated with an
increase in parasympathetic tone, and coffee did not increase
cardiac arrhythmia. The authors concluded that coffee
ingestion is safe and not associated with adverse CV outcomes
in post-MI patients (27). A more recent study showed that
acute caffeine ingestion signiﬁcantly decreased high-
sensitivity C-reactive protein levels in 2 groups of patients
with and without CHD compared with placebo (28).
Coffee and CHF
A recent large meta-analysis reported a U-shaped relation-
ship between coffee consumption and the incidence of CHF.
Five independent prospective studies evaluating coffee
consumption and CHF risk, from January 1966 through
December 2011, were included in the meta-analysis. A total
6,522 heart failure events were recorded among the 140,220
participants during follow-up. A statistically signiﬁcant
association between coffee and CHF was observed, with the
strongest inverse association noted for 4 servings per day
with increased CHF risks for both higher and lower levels of
coffee consumption (Fig. 3). There was no evidence that the
relationship between coffee and risk of heart failure varied by
sex or by baseline history of MI or diabetes (29).
Coffee and Arrhythmias
Data linking coffee consumption to increased risk of ar-
rhythmias are inconsistent. Early animal studies indicated
that coffee appeared to cause arrhythmias in a caninemodel (30).
Yet, more recent studies have suggested that coffee appears not
to increase arrhythmias; to the contrary, long-term coffee
drinking might actually reduce the risk of abnormal cardiac
rhythms. In aKaiser Permanente study of 130,054 adults living
in California, an inverse relationship between habitual coffee
Figure 2 Adjusted Hazard Ratios for Risk of Death as a Function of Coffee Consumption
Association of daily coffee consumption with total and heart disease mortality among men (A) and women (B). Error bars indicate 95% conﬁdence interval. Adapted from
Freedman et al. (25).
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observed during long-term follow-up. A total of 3,137
persons were hospitalized over a mean follow-up period of
17.6 years. Coffee intake correlated inversely with cardiac
arrhythmia (Fig. 4). The relationship was consistent in men,
women, whites, blacks, and persons younger than or older
than 60 years of age. The authors concluded that people who
drank 4 cups of coffee per day tended to have fewer cardiac
arrhythmias, including less atrial ﬁbrillation (AF) (31).
Considering the effects of caffeine in isolation, controlled
interventional studies show that in normal adults, even
high-dose caffeine does not affect prevailing cardiac rhythm
and rate, and, moreover, does not cause clinically signiﬁcant
ventricular or supraventricular arrhythmias (32). In 5
placebo-controlled trials, caffeine in doses as high as 500mg/day (equivalent to 4 or 5 cups of coffee) did not increase
the frequency or severity of ventricular arrhythmias (33). In
a prospective interventional electrophysiological study,
ingestion of 275 mg of caffeine did not signiﬁcantly alter
inducibility or severity of arrhythmias (34).
The mechanisms conferring potential protection against
arrhythmias are still largely unknown, but according to 1
hypothesis, caffeine inhibits adenosine in the heart, as it
does in the brain. Endogenously secreted adenosine affects
cardiac electrical conduction and cardiomyocyte repolariza-
tion and may cause shortening of the atrial and ventricular
refractory periods, thereby predisposing to arrhythmias.
Caffeinated coffee intake could theoretically confer car-
dioprotection by attenuating these negative effects of endog-
enous adenosine (31).
Figure 3 Coffee and Risk of Heart Failure
Association between heart failure and cups of coffee per day compared with no
consumption. Relative risk (solid line) and 95% CI (dashed lines). Adapted with
permission from Freedman et al. (25) and Mostofsky et al. (29).
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receptor blocker might reduce the efﬁcacy of exogenously
administered adenosine for the treatment of paroxysmal
supraventricular tachycardia. One case-control study found
that ingestion of caffeine within 4 h before a 6-mg adenosine
bolus signiﬁcantly reduced its effectiveness for the conver-
sion of supraventricular tachycardia to normal sinus rhythm
(35). A large prospective, observational study found that
drinking coffee, even 6 cups/day, was not associated with
any QT interval abnormalities that might predispose to
serious arrhythmias (36).
In the Women’s Health Study, 33,638 women older than
45 years of age and free of CV disease and AF at baseline
were prospectively followed for incident AF from 1993
through 2009. During a median follow-up of 14.4 years in
this large cohort of initially healthy women, caffeine
consumption was not associated with an increased risk of
incident AF (37). In the Danish Diet, Cancer, and Health
study, 47,949 participants 50 to 64 years of age were fol-
lowed for a mean of 5.7 years. Caffeine consumption in the
form of coffee, tea, and cola was not associated with the risk
of the development of AF or ﬂutter (38). These results were
replicated in the Framingham Heart Study cohort of 4,526
participants; during a prospective follow-up of 4 years, no
signiﬁcant association between coffee consumption and AF
risk was noted (39).
Coffee and Stroke
Coffee may reduce the risk of ischemic stroke. A recent
meta-analysis of 7 prospective studies with 442,098 partic-
ipants, 6,962 stroke events, and follow-up of 2 to 24 years
demonstrated that 1 to 3 cups of coffee were associated witha decreased risk of stroke (RR: 0.82, 95% CI: 0.74 to 0.90,
p < 0.001). The evaluation of the risk of stroke in the
general population consuming 3 to 6 cups of coffee per day
showed a signiﬁcant reduction (RR: 0.79, 95% CI: 0.68 to
0.92, p ¼ 0.003). By contrast, habitual consumption of >6
cups of coffee per day was not associated with any effect on
stroke risk (RR: 1.00, 95% CI: 0.76 to 1.32, p ¼ 0.97). The
authors concluded that coffee consumption is not associated
with a higher risk of stroke and that habitual moderate
consumption may exert a protective effect (40).
In the Swedish Mammography Cohort, 34,670 women
without a history of CV disease or cancer were followed for
a mean of 10.4 years. The multivariable RRs of total stroke
across categories of coffee consumption (<1 cup/day, 1 to 2
cups/day, 3 to 4 cups/day, and 5 cups/day) were 1.00, 0.78
(95% CI: 0.66 to 0.91), 0.75 (95% CI: 0.64 to 0.88), and 0.77
(95% CI: 0.63 to 0.92), respectively (p for trend¼ 0.02). The
ﬁndings suggested that coffee consumption was associated
with a statistically signiﬁcant lower risk of stroke (41). This
inverse association of coffee consumption and mortality from
stroke was also observed in a diabetic population (Fig. 5) (42).
An analysis of a prospective group of >83,000 women from
the Nurses’ Health Study who were free of CV disease and
cancer at baseline found that coffee consumption was asso-
ciated with a modest but statistically signiﬁcant reduction in
the risk of stroke during the 24-year follow-up period (43).
Exactly how coffee lowers the risk of stroke is unknown, but
postulated mechanisms include coffee’s anti-inﬂammatory
and insulin-sensitizing effects (44–46).
Coffee Consumption and Mortality
In the National Health and Nutrition Examination Survey I,
6,594 participants 32 to 86 years of age with no history of
CV disease at baseline were prospectively followed for 8.8
years. Coffee intake of participants who were 65 years of age
or older exhibited a dose-response protective effect whereby
increasing habitual consumption of coffee was associated
with lower RRs of adverse CV events and heart disease
mortality (Fig. 6) (47).
In another study, 41,736 men and 86,214 women with no
history of CV disease or cancer at baseline were followed for
18 years (men) and 24 years (women) to assess the associ-
ation between coffee consumption and CV mortality, cancer,
and all-cause mortality. An inverse association between
coffee consumption and all-cause mortality was seen mainly
due to a moderately reduced risk of CV disease mortality and
was independent of caffeine intake; decaffeinated coffee was
also associated with a small reduction in all-cause and CV
disease mortality (48).
In the recent National Institutes of Health-AARP Diet
and Health Study, 229,119 men and 173,141 women were
followed from 1995 through 2008 to examine the association
of coffee drinking with subsequent total and cause-speciﬁc
mortality. Participants were 50 to 71 years of age at baseline
and were excluded if they had a personal history of cancer,
Figure 4 Coffee Consumption and Risk of Arrhythmias
Adjusted hazard ratio (no coffee take is referent ¼ 1) of arrhythmia diagnoses by coffee intake. Error bars indicate 95% conﬁdence interval (CI). Adapted from Klatsky et al. (31).
AF ¼ atrial ﬁbrillation; SVT ¼ supraventricular tachycardia.
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was increased in coffee drinkers, coffee drinkers were also
more likely to smoke. After adjustment for tobacco smoking
and other potential confounders, men who drank 6 cups
of coffee per day had a 10% lower risk of death and womenFigure 5 Coffee Intake in Diabetic Subjects
Adjusted hazard ratios of total, cardiovascular (CV) disease, coronary heart disease (CHD
diabetes mellitus. Error bars indicate 95% conﬁdence interval (CI). Adapted from Bidel ethad a 15% lower risk, irrespective of whether they drank
caffeinated or decaffeinated coffee. Inverse associations were
observed for deaths due to heart disease, respiratory disease,
stroke, injuries and accidents, diabetes, and infections, but not
for deaths due to cancer (25).), and stroke mortality by volume of coffee consumption among subjects with type 2
al. (42).
Figure 6 Coffee Over Age 65
Relative risk of cardiovascular disease (CVD) and heart disease mortality by level of caffeinated beverage intake in individuals 65 years of age and older. Error bars indicate 95%
conﬁdence interval (CI). Adapted from Greenberg et al. (47).
Figure 7 Coffee and Depression
Multivariate-adjusted relative risk (RR) of clinical depression according to caffeine
consumption (p for trend ¼ 0.02). Error bars indicate 95% conﬁdence interval.
Reproduced with permission from Lucas et al. (50).
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Coffee consumption is also associated with various other
health effects. For instance, coffee may reduce the risk of
depression, a known risk factor for the development of CV
disease, as well as an independent predictor of poor prog-
nosis (49). In a recent longitudinal study of 50,739 women,
ingesting 4 cups of coffee daily signiﬁcantly decreased the
RR of depression (Fig. 7). The effect may be due largely to
the caffeine content because women consuming decaffein-
ated coffee did not show a reduced risk (50). Coffee
consumption may also beneﬁt efforts at weight control,
increasing the thermic effect of food and fat oxidation in
normal-weight subjects (51).
Other beneﬁcial health effects of coffee may include
reduced risks of Alzheimer’s dementia (52,53) and other
diseases of the central nervous system including Parkinson’s
disease (54–56). Additionally, coffee may improve asthma
symptoms, probably through caffeine, which is a methyl-
xanthine bronchodilator, and enhance performance in sus-
tained high-intensity exercise (57,58). Coffee may prevent
symptomatic gallstones (59) and be associated with protec-
tion against some infectious and malignant diseases,
particularly of the liver (60–62).
All of this is not to say that coffee is without its own
risks. Many individuals experience palpitations, anxiety,
tremulousness, and trouble sleeping after drinking coffee,
particularly when it contains higher doses of caffeine (63).
The polycyclic aromatic hydrocarbon-inducible cytochrome
P450 1A2 participates in the metabolism of caffeine and
a number of drugs, including certain selective serotonin
reuptake inhibitors (particularly ﬂuvoxamine), antiarrhyth-
mics (mexiletine), antipsychotics (clozapine), psoralens,idrocilamide and phenylpropanolamine, bronchodilators
(furafylline and theophylline), and quinolones (enoxacin),
can aggravate the unwanted secondary effects of coffee by
inhibiting this isoenzyme (64). Decaffeinated coffee may be
a good option, particularly because many of coffee’s potential
beneﬁts likely derive from sources other than its caffeine.
Moreover, high levels of caffeine (>750 mg/day) may
increase urine output and urinary calcium and magnesium
excretion, which has implications for bone health (65).
Caffeinated coffee increases the risk of bone loss (66,67) and
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of calcium lost from consuming 1 cup of coffee can be offset
by mixing in just 2 tablespoons of milk (66). Moreover,
a daily glass of milk might offset the calcium loss and
reductions in bone mineral density due to coffee consump-
tion (67). Additionally, the human body develops tolerance
to caffeine usually after 3 to 5 days of regular use and
kidneys ensure that proper homeostatic conditions are
maintained, which attenuate the already limited diuretic
effects of kidney (69).Coffee and Clinical Considerations
People who consume coffee typically do so on a daily basis,
often due to caffeine dependence. Caffeine is a central
nervous system stimulant, and its regular use typically causes
mild physical dependence as evidenced by the development
of tolerance, withdrawal symptoms (headaches, irritability,
fatigue, depressed mood, anxiety, and difﬁculty concen-
trating), and cravings with abstinence (70,71). Notwith-
standing, daily caffeine use generally does not threaten one’s
physical health and emotional/social well-being the way that
many addictive drugs like alcohol, opiates, cocaine, and
methamphetamines do; thus, substance abuse experts
generally do not consider caffeine dependence a serious
addiction (70). Indeed the tendency for coffee to promote
habitual daily consumption may ultimately turn out to be
advantageous if its myriad potential health beneﬁts are
conﬁrmed.
Caffeine, in moderate daily doses of w300 mg, or w3
cups of coffee, appears to be safe and harmless for healthy
adults. Conversely, ingesting 10 times that amount of
caffeine in a short period could be lethal (72). Moderation,
tending toward 2 or 3 to as much as 4 cups a day if tolerated,
seems a reasonable suggestion.Conclusions
The currently available evidence on CV effects related to
habitual coffee consumption is largely reassuring. Coffee can
be included as part of a healthy diet for the general public
and also for those with increased CV risk or CV disease.
Those with dyslipidemia may consider brewed and ﬁltered
coffee as opposed to preparations made from boiling beans
without ﬁltering. While many of coffee’s beneﬁts probably
derive from its caffeine content, decaffeinated coffee seems to
offer some health beneﬁts too and may be a reasonable option
for those who experience uncomfortable effects from caffeine
stimulation. Drinkers of caffeinated coffee in particular
might be advised to ensure adequate calcium consumption
from dietary sources to guard against potential adverse
outcomes related to bone health. Finally, it is possible that
individuals who consume coffee differ in other important
dietary and sociological aspects from the nonconsumers.
Therefore, the possibility that coffee consumption may beacting as a surrogate marker of some other dietary or lifestyle
risk factor cannot be fully excluded.
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